Good and continue markets. Craig afternoon, Heron operator. this and and you, Thank everyone, oncology be to headway Quarter CEO Heron leading Earnings in I'm new hospital thrilled Therapeutics as welcome XXXX Call. make the I'm we Collard, organization, of Therapeutics, to First the to the
quarter recent my performance, give Today, year, of increase highlight XX%. net achievements, forward. quarter of I'll million, from first last provide my importantly, into an Total were the but and strategic up in an some business $XX.X our insight weeks discuss assessment same over overview the more of product four in vision million for $XX.X key first revenues our moving the
was the our make We business, both we remain continue to opportunity approved about progress newly ZYNRELEF this product in but steady for side our market which March the of launched excited year. and of oncology on APONVIE,
will limited can our Starting had has well variety launch an a profile a a we counter works the clinical market, approved, reasons. choice The of used. the slow that, date, indications to product sNDA competing PDUFA procedures the huge we Despite differentiated and has with a of variety treat. since within product across our expand ability of for drug if that of that filed uptake be has number a indications. realize when label ZYNRELEF, To October I XX in
needle vial, in suite drugs. issues that van some improve and game a programs compared could syringe products we started to the access be our has address or ultimately other a during the of have multiple the To recently changing. slowed from nature faced vial including surgery viscous the enhancement withdrawal prefilled preparation, the The handling, of we to
really which to I sales work used I application product when trying messages field time the that general product. far, happens been issues. seen joining the out to to Since so in was always and the performance our use report, mixed assess in surgeries. the Previously, get helpful able understand with have to in product make product representatives, to about of to product. I had and company, I've knee happy that find I X I'm the draw our the heard issues more it viscosity trying of what would difficult the vial, ZYNRELEF
training this that, nursing staff nature these from even The routine and is became application determined few The second the prep is it surgeon and using admitted arrives. requires as I it is after part but the of different, day. watching the can times, just a the the What now normal product before saw replicate I we complex. staff, in surgeries success not that
I think of launch own on, the was head product, and company training reps didn't our of more address early issue going that inefficiencies. our to in require the this highlighted did understand and this our not
are quickly launched launch challenges and on is move succeed. back track. good here All that The and products not part are the it's that they the late generally have prepared when companies can this get too companies to generally ultimately that
joining postoperative substance NKX the Now, nausea IV antagonist to to product a APONVIE, only injectable the for prior launched emulsion the and moving month APONVIE, vomiting. was my is company. receptor an indicated
relief. very will be profile advantages was is clinical our a point in this As a relief, a market. in has We and believe product with that very large portfolio product overlap call and APONVIE in competes successful and great a was marketing in great
its ways as we year. shareholders encouraging, will and this progress look is our to receptivity maximize to the throughout for the potential While we launch update initial
be might for move forward. David to thought we the as it some insight as to a direction helpful whole Before over turning into a the the strategic and call financial view give a business into I review,
company, functions has thorough as to of for and to determine value unit. that practices trying much develop spend, the the internal a The have department company Since a shareholders. joining been my and to I spent review do company's strategies a long-term time to all goal the each to allows the how business understand maximize headcount, plan company
more be a to not realistic understanding improvement of coming of capital Although tell can cash and reduction our and implementation of determine a of burn forecast changes efficiency better my soon, a review moving have requirements I operational much product complete, many the I including you accurately company that and is will the forward.
company, Shortly after the the change, have the Grillot, in with Jason in past executive major the company. our hired efforts. I reporting was implemented I flatten structure lead sales I I to first the which and whom joined to marketing worked
force and the changes these many will our continue reporting. structure, with and including to updated accounting of Jason data believe and message, things many improve to improving be later sales I will commercial be products. support, to alignment, management uptake the marketing others the targeting,
be headcount. provide and in detail the more Other I and dependency near future. Again, implementing include consultants less will expense outsourcing will on cuts reduction in
the concern As you this process some shareholders. I've causing among well-positioned be assessing our and been our future. uncertainty of to I business recognize ensure aspects we may know, all for are that
strategic this with We we resources we and you and information possible to every way of input as our in changes keep direction you've navigate want committed you and the your be that as We understand as the time value your process. about providing company, will We to informed that support. invested are coming. step much
and you plan will more we reasons the changes about the behind them. with share implement details soon. We to
to stakeholders. more meet a company that stronger, Our of customers equipped the to goal better is sustainable is create and needs our
we through I appreciate your patience and understanding as this work process.
and our position with success, sharing forward will look are changes confident information for us that to soon. more We long-term you we
Go ahead, David.
